BioSpace News Archive

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Tiziana Life Sciences disclosed the receipt of a notice on July 19, 2023 from the Nasdaq Stock Market LLC that the Company is not currently in compliance with the $1.00 Minimum Bid Price Requirement for continued listing of the Company’s common shares on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5450.

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2023 financial results and provided a corporate update.

Horizon Therapeutics plc announced that its Phase 2 clinical trial evaluating daxdilimab for the treatment of SLE did not show a statistically significant separation between daxdilimab and placebo on the primary endpoint, which was the proportion of patients to achieve a British Isles Lupus Assessment Group 2004 Index-based Combined Lupus Assessment response and an oral glucocorticoid dose of ≤7.5 mg/day, which represented a reduction from the Baseline OGC dose at 48 weeks.